netFormulary Sunderland Joint Formulary NHS
NHS Sunderland Clinical Commissioning Group
City Hospitals Sunderland NHS Foundation Trust
 
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
Notes:


Chapter Links...
 Details...
06.01.02.03  Expand sub section  Other antidiabetic drugs
Pioglitazone
(Thiazolidinedione)
View adult BNF View SPC online
Formulary Tablets: 15mg, 30mg, 45mg 
   
Repaglinide
(Metiglinide)
View adult BNF View SPC online
Formulary Tablets: 500 micrograms, 1mg, 2mg 
   
Acarbose
View adult BNF View SPC online
Alternatives
Green +
Tablets: 50mg*
*For existing patients only, no new patients. Unless for reactive hypoglycaemia on advice of specialist 
   
06.01.02.03  Expand sub section  DPP-4 inhibitors
Alogliptin
View adult BNF View SPC online
Formulary

Tablets: 6.25mg, 12.5mg, 25mg

 
   
Linagliptin
View adult BNF View SPC online
Formulary

Tablets: 5mg

 
   
Saxagliptin
View adult BNF View SPC online
Formulary

Tablets: 2.5mg, 5mg

 
   
Sitagliptin
View adult BNF View SPC online
Formulary

Tablets: 25mg, 50mg, 100mg

 
   
06.01.02.03  Expand sub section  GLP-1 mimetics
Dulaglutide
View adult BNF View SPC online
Formulary
Green +
Injection (pre-filled pen): 0.75mg/0.5ml, 1.5mg/0.5ml 
   
Exenatide
View adult BNF View SPC online
Formulary
Green +
Injection (250 microgram/1ml pre-filled pens): 5 microgram/dose, 10 microgram/dose

MR Pen: 2mg pen 
   
Liraglutide
View adult BNF View SPC online
Formulary
Green +

*Injection (pre-filled pen): 18mg/3ml (0.6mg/dose)

*Liraglutide is only approved on the Sunderland Joint Formulary for the treatment of diabetes. Its use for any other indication is considered non-formulary.

 
Link  NICE TA203: Diabetes (type 2) - liraglutide
   
Lixisenatide
View adult BNF View SPC online
Formulary
Green +
Injection (pre-filled pen): 10 micrograms/dose, 20 micrograms/dose

Consider as 1st line G-L-P1 receptor agonist lowest acquisition cost 
   
06.01.02.03  Expand sub section  SGLT2 inhibitors
Canagliflozin
View adult BNF View SPC online
Formulary
Green +
Tablets: 100mg, 300mg 
Link  NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
   
Dapagliflozin
View adult BNF View SPC online
Formulary
Green +
Tablets: 5mg, 10mg 
Link  NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
   
Empagliflozin
View adult BNF View SPC online
Formulary
Green +

Tablets: 10mg, 25mg

 
Link  NICE TA336 : Empagliflozin in combination therapy for treating type 2 diabetes
   
06.01.02.03  Expand sub section  Other to top
 ....
 Non Formulary Items
Albiglutide  (Eperzan)

View adult BNF View SPC online
Non Formulary
 
Alogliptin / metformin  (Vipdomet)

View adult BNF View SPC online
Non Formulary
 
Alogliptin / pioglitazone  (Incresync)

View adult BNF View SPC online
Non Formulary
 
Canagliflozin / metformin IR  (Vokanamet)

View adult BNF View SPC online
Non Formulary
 
Dapagliflozin / metformin  (Xigduo)

View adult BNF View SPC online
Non Formulary
 
Empagliflozin and Metformin  (Synjardy)

View adult BNF View SPC online
Non Formulary
 
Empagliflozin and Metformin  (Synjardy)

View adult BNF View SPC online
Non Formulary
 
Exenatide prolonged release  (Bydureon▼)

View adult BNF View SPC online
Non Formulary
Link  NICE TA248: MR exenatide
 
Linagliptin/ metformin  (Jentadueto)

View adult BNF View SPC online
Non Formulary
 
Nateglinide  (Starlix)

View adult BNF View SPC online
Non Formulary
 
Pioglitazone and Metfomin  (Competact)

View adult BNF View SPC online
Non Formulary
 
Rosiglitazone  (Avandia)

View adult BNF View SPC online
Non Formulary
 
Rosiglitazone and Metformin  (Avandamet)

View adult BNF View SPC online
Non Formulary
 
Saxagliptin and metformin  (Komboglyze)

View adult BNF View SPC online
Non Formulary
 
Sitagliptin and Metformin  (Janumet)

View adult BNF View SPC online
Non Formulary
 
Vildagliptin

View adult BNF View SPC online
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   

Amber

These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

Green +

Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. An information leaflet may be provided in order to facilitate ongoing prescribing in primary care.   

Green

These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.   

netFormulary